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Assessment of Glucose Kinetics with Real-Time Continuous Glucose Monitoring 
during Labor 
Aim: Changes in glucose levels during labor have not been sufficiently investigated in 
pregnant women. Using real-time continuous glucose monitoring, we aimed to assess 
glucose kinetics during labor among pregnant women with gestational diabetes 
mellitus (PwGDM), and those with normal glucose tolerance (PwNGT). 
Methods: Japanese PwGDM and PwNGT who had planned a transvaginal delivery at 
Okayama University Hospital were enrolled. The correlation between changes in 
glucose levels during labor among the PwGDM and PwNGT groups at four time 
periods was assessed: (i) active phase of 1st stage of labor; (ii) 2nd stage of labor; (iii) 
postpartum 0–12h; and (iv) postpartum 12-48h. 
Results: In total, 18 and 22 PwGDM and PwNGT, respectively, were enrolled. During 
labor, both groups had similar changes in glucose levels over time, which peaked during 
period 3. The main effect of glucose level changes was the labor period (P<0.001), not 
the presence of gestational diabetes mellitus. Furthermore, differences in glucose levels 
in the PwGDM group were observed between periods 1 and 2 (P=0.037), 1 and 3 
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(P=0.024), 3 and 4 (P=0.005); differences in glucose levels in the PwNGT group were 
observed between periods 3 and 4 (P=0.024). 
Conclusions: During labor, both PwGDM and PwNGT groups showed similar changes 
in glucose levels over time. During delivery, the PwGDM who regularly measured their 
own glucose levels could be managed using the same nutritional management methods 
as those for PwNGT. 
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According to the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG), the frequency of gestational diabetes mellitus (GDM) has increased by 
fourfold in Japan since 2011 and has increased by 19.4% in the United States.[1, 2] As 
such, the management of patients with GDM during pregnancy and labor has become an 
imperative issue in healthcare. Both the Japanese and American guidelines recommend 
that the blood glucose (BG) levels of pregnant women with GDM (PwGDM) be 
maintained at 70–110mg/dL during pregnancy or at 120mg/dL during labor. [3, 4] 
As continuous glucose monitoring (CGM) levels can be recorded on a device every 
5min, changes in glycemic trends, such as hyperglycemia and hypoglycemia, which 
may have been previously overlooked during self-monitoring of blood glucose 
(SMBG), can now be assessed. Furthermore, changes in the mother's glucose levels 
(GL) can be improved during pregnancy using CGM; such improvements can reduce 
the risk of maternal-fetal complications.[5–7] Sensor glucose (SG) measures GL from 
the interstitial fluid surrounding the subcutaneous tissue cells so that it is possible to 
detect differences in the accuracy between the SG and the SMBG levels.[8] However, 
changes in GL during labor have not been sufficiently investigated in PwGDM or 
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pregnant women with normal glucose tolerance (PwNGT). Therefore, this study aimed 
to clarify the changes in GL during labor in PwGDM and PwNGT. 
 
Methods 
Ethical Statements  
This study was approved by the ethics committee of Okayama University (April 2016, 
approval number 1604-035) and conforms to the provisions of the Declaration of 
Helsinki, as revised in Fortaleza, Brazil on October 2013. Informed consent was 
obtained from all patients. 
 
Study Design, Patients, and Data  
In this case–control study, Japanese PwGDM (all cases) and PwNGT (random 
cases) who had planned a transvaginal delivery from May 2016 to March 2018 at 
Okayama University Hospital were enrolled. Pregnant women whose babies were 
delivered before data collection began, whose delivery method was changed to 
cesarean section during measurement, or who were not attached to any measurement 
device because of in sufficient measuring devices during over lapping deliveries were 
excluded. Pregnant women who were taking any psychotic medication or steroids up 
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until delivery, had labor complications, or for whom there were other reasons they 
were unable to undergo examinations, and who were already on continuous insulin 
treatment during pregnancy, were also excluded. Patient characteristics, such as age, 
height, pre-pregnancy weight, body mass index (BMI), pre-delivery weight, total 
weight gain during pregnancy, body temperature on admission, time of first or second 
labor stages, age of gestation at delivery, and effacement, station, and Bishop score at 
device installation were collected. Additionally, data were collected on primiparity, 
family history of diabetes, vacuum extraction, the use of epidural anesthesia for 
delivery, and the induction of labor. The patient selection flowchart is shown in 
Figure1. BG dynamics during parturition were extrapolated on the assumption that it 
continued until after parturition. Based on previously published studies, [9–11] the 
estimated mean BG levels during parturition in the PwGDM and PwNGT groups 
were 90 and 110mg/dL, respectively. Based on published data, [10,11] we used α of 
0.05 and β of 0.20. Additionally, we used 20mg/dL as the standard deviation for each 
group. Thus, 17 cases, in each group, were required for the statistical test. Integrated 
statistics software STATA (Stata Corp LLC) was used for the analysis. 
Diagnosis and Management of GDM  
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Patients underwent a 2-h 75-g oral glucose tolerance test (OGTT) as recommended by 
the Japan Society of Obstetrics and Gynecology.[12] GDM was defined according to 
the criteria outlined by the IADPSG, and the OGTT results were used to identify 
women with GDM as recommended by the Japanese Society of Diabetes and Pregnancy 
(JSDP). [13] All pregnant women in the study were followed up according to a routine 
pregnancy care program: hospital visits every 4weeks until 26 weeks, every 2 weeks 
until 36 weeks and weekly after 36weeks of pregnancy. During the first week after 
diagnosis of GDM, self-monitored plasma glucose measurements were recommended 
4–7 times daily according to the risk of GDM (e.g., four times daily meant before 
breakfast and 2 h after each main meal, whiles even times daily included additional 
checks before lunch and dinner, and at bedtime). Additionally, nutritional guidance was 
provided every 4weeks, while insulin doses were adjusted with the assistance of an 
experienced diabetologist every 2 or 4weeks. 
 
Real-Time CGM and SMBG 
Medtronic Minimed 620G (CGM transmitter, Enlite Glucose Sensor; Care-link Pro) was 
used for real-time CGM measurements, while the Glutest Neo Super (Sanwa Kagaku 
Kenkyusho) was used for SMBG.[9, 14, 15] These devices are ISO certified, and thus, 
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the measurements were presumed to be highly accurate. Moreover, SG levels comparable 
to BG levels can be obtained using these devices.[16] CGM levels were measured via SG. 
The SG monitor was fitted on the upper, outer arm where, with greater amounts of 
subcutaneous fat, interference with the delivery would be unlikely. SMBG was performed 
using the arm on which the device was fixed. For all cases, the device was fitted on the 
patient during hospitalization, after contractions began, and once the rupture of 
membranes had been confirmed, or if labor was induced. SG was calibrated using BG 
levels obtained from SMBG as follows. In all cases, the first calibration was performed 
when the alarm rang, approximately 2 h after the CGM device was fitted. Thereafter, from 
the beginning of labor until the delivery of the baby, BG levels were measure data fixed 
time, at least 4 times daily, using SMBG. Once the baby was born and the postpartum 
procedures were completed, BG calibrations were taken at least two times daily. Changes 
in GL for the PwGDM and PwNGT groups were measured from the commencement of 
contractions until 48h after parturition. A sample of the CGM levels for one patient is 
shown in Figure2. Changes in GL from the 
activelaborphaseto48hafterparturitionforthePwGDMandPwNGTgroupsarerepresentedby
theaverage GL for each period. 
SG Measurements and Factors for Analysis  
 10 
The 48-h period following parturition was divided into four time periods as follows: (i) 
active phase of 1st stage of labor (i.e., the active phase); (ii) 2nd stage of labor; (iii) 
postpartum 0–12h; and (iv) postpartum 12–48h. The active labor phase was defined as 
the time when the cervix was dilated by more than 4cm,100% effaced, and at −2 stations 
or more.[17] 
GL dynamics were compared between the two groups by determining the mean GL for 
each group in each time window. 
Delivery of PwGDM 
This study adhered to the American College of Obstetricians and Gynecologists 
(ACOG) and JSDP management methods for deliveries among pregnant women with 
abnormal glucose metabolism.[16] Therefore, regarding the timing or amount of food 
eaten, PwGDM were allowed to eat or drink during labor within the limits of caloric 
management provided by the hospital. Subcutaneous in jection of fast-acting insulin 
was administered directly before food consumption (as directed by the doctor in charge) 
during the latent phase of labor or after the commencement of labor. Pre-meal insulin 
was discontinued following the active phase. 
GL control was achieved before eating and drinking, using an insulin sliding scale, in 
line with hospital regulations. Hypoglycemia was defined as a GL <60mg/dL. In such 
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cases, the patient was either given food containing 5–10g of glucose or 150–200mL of 
soda. GL ≥70mg/dL but ≤150mg/dL required no treatment, while 1 unit of fast-acting 
insulin was administered subcutaneously for GL >150mg/dL. Thereafter, for each GL 
increase of 50mg/dL, 1 unit of fast-acting insulin was administered subcutaneously. The 
intravenous drips used for inducing labor and for newborn resuscitation at this hospital 
contained extracellular fluid (glucose content: 0%); thus, glucose was not loaded. For 
the PwGDM group, SMBG was continued during the postpartum period before and 2h 
after meals, and all insulin doses were then discontinued after 48h. 
Statistical Analysis 
The patient characteristics were compared using Fisher's exact test for categorical 
variables and the Mann–Whitney U test for continuous variables, when appropriate. 
Continuous variables were reported as medians (ranges). Missing values in CGM 
data were replaced with the peripheral average values based on the levels at 5, 10 and 
15min (30min in total) before and after the missing value. The GL differences during 
the progression of labor were examined using split-plot analysis of variance and post 
hoc tests (tests of within-subject effects) in the PwGDM and PwNGT groups. For the 
post hoc tests, unpaired and paired ttests were corrected using Bonferroni's method. 
The level of significance was set at 5%. All statistical analyses were performed using 
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IBM spss statistics version 23.0 (IBM Corp.), and a two-sided P-value <0.05 was 
considered statistically significant. A third-party organization, Suzuki Iryō Tōkei 
Services (Suzuki medical statistics services, https://medicalslide.jimdo.com/) used the 
data from this study for the above statistical analysis. The analysis was certified by 
Editage × Stagen (Supporting Information S1). 
Results 
Among the 93 pregnant women initially enrolled, 42 (45.1%) were excluded. Of the 51 
women who had transvaginal deliveries, 25 (26.9%) and 26 (28.0%) were included in 
the PwGDM and PwNGT groups, respectively. In total, 8 of 93 (8.6%) women were 
further excluded due to missing data as well as two cases of overt diabetes during 
pregnancy and a case of diagnosis of type 1 diabetes after delivery. Finally, 40 patients 
(18 [19.4%] and 22 [23.6%] in the PwGDM and PwNGT groups, respectively) were 
included in the analysis (Figure.1). The patient characteristics as well as the newborn 
characteristics, including birth weight, height, chest measurement, umbilical cord blood 
gas, and the first blood sugar level, are shown in Table1. The prepregnancy body weight 
and BMI of women in the PwGDM were higher than those in the PwNGT group 
(P=0.047, 0.066). Total weight gain during pregnancy of women in the PwNGT were 
higher than those in the PwGDM group (P=0.0075). Among infants, the average first 
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BG measurement was significantly lower among infants whose mothers were in the 
PwGDM group, although it was above the cut-off for hypoglycemic GL (<50mg/dL). 
No significant difference was observed between the PwGDM and PwNGT groups in 
any of the other characteristics investigated. 
In total, two (11.1%) patients required insulin during the latent phase of labor (before 
period 1); this decreased to zero patients after the active labor phase (period 1). No 
patient received insulin after period 2. Hence, the total amount of insulin used among all 
patients decreased from 14 units to 0 between the latent and the active phase. The 
details of the two cases that required insulin treatment after the initiation of labor pains 
are shown in Table 2. 
Changes in GL from the active labor phase to 48h after parturition for the PwGDM 
and PwNGT groups are represented by the average GL for each period (Figure.3). The 
mean ± standard deviation (SD) GL of the PwGDM and PwNGT groups at the various 
periods were as follows: period 1, 102.5±27.26 mg/dL and 99.9±22.81 mg/dL; period 2, 
115.9±34.15 mg/dL and 105.1±27.27 mg/dL; period 3, 127.9±28.37 mg/dL and 
115.4±23.37 mg/dL; period 4, 106.9±15.77 mg/dL and 99.05±14.33 mg/dL, 
respectively. During labor, the PwGDM and PwNGT groups had similar changes in GL 
over time. GL peaked in both the PwGDM and PwNGT groups in period 3. A 
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significant difference was observed in the main effect during the labor period 
[F(2.12,80.51) = 9.484, P=0.00014], but not for the presence of GDM [F(1,38) = 2.069, 
P=0.159] or in their interaction [F(2.12,80.51) = 0.512, P=0.612]. During labor, both 
groups had similar changes in GL over time, which peaked during period 3. 
Furthermore, differences in GL in the PwGDM group were observed between periods 1 
and 2 (P=0.037), 1 and 3 (P=0.024), and 3 and 4 (P=0.005), as well as in the PwNGT 
group between periods 3 and 4 (P=0.024). For the PwNGT group, a significant 
difference was observed between periods3 and 4 (P<0.05). However, as ignificant 
difference was not observed in period4 for both the PwGDM and PwNGT groups 
(P=0.109) (Figure.3). 
Discussion 
Hyperglycemia during labor is associated with adverse infant condition ssuch as non-
reassuring fetal status, birth asphyxia and neonatal hypoglycemia. Maintaining an 
appropriate BG level in mothers during labor is associated with the prevention of 
newborn and infant complications. [18–21] However, no standard strategies for 
controlling GL during labor have been established. Adequate energy intake for 
PwGDM during labor plays an important role in avoiding adverse events from glucose 
metabolism disorders. ACOG recommends that mothers fast during labor, and GL are 
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then measured after the consumption of glucose during the latent and active labor 
phases. For a 60-kg pregnant woman, a continuous administration of 1.4–
2.1mg/kg/min of 5% intravenous glucose infusion is recommended. [1] In Japan, the 
strategy used for the control of GL during labor is similar to that stipulated in the 
ACOG guidelines.[4] However, changes in GL during labor among PwGDM have not 
been sufficiently investigated. To the best of our knowledge, this study is the first to 
evaluate the changes in GL during labor among PwGDM and PwNGT. 
There sults from this study revealed no significant difference in the average GL 
among PwGDM and PwNGT between periods 1 to 4. A significant difference was 
observed in the main effect during the labor period, but not for the presence of GDM. 
The mother's activity between the active labor phase and period 2 is considered to be 
strenuous, and energy is expended to maintain this level of intense exercise. Hence, 
the available glucose must be increased as the body supplies the required amount of 
glucose during childbirth. [22] However, during the labor period, labor pain makes it 
difficult for the mother to freely eat or drink. Why did GL increase as parturition 
neared? Cortisol is a diabetogenic hormone that causes increased GL. Research has 
shown that pregnant women had high levels of cortisol during the last stage of 
parturition because it was crucial for fetal respiratory function.[23–25] In this study, 
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although glucose was not administered continuously, GL gradually increased 
throughout the delivery, with the average GL peak for both the PwGDM and PwNGT 
groups occurring in period 3 directly after parturition. Although levels of cortisol were 
not determined in this study, from the above explanation, it was considered that 
cortisol levels may explain the increase in GL from parturition until postpartum. 
The glucose concentrations of PwGDM and PwNGT decreased gradually as they 
moved towards period 4. In this study, a significant difference was observed in GL 
between time periods 3 and 4 in both PwNGT and PwGDM groups. Pathologically, 
the required insulin level for PwGDM should rapidly decrease directly after the 
placental expulsion, at least to the amount that was required before pregnancy.[26, 27] 
The decrease in the average GL in the transition period between time periods 3 and 4 
for PwGDM and PwNGT was so profound that it resulted in a significant difference. 
In contrast, the decrease was less for PwGDM. In the very early stages of the 
postpartum period (directly after and up until 48h after parturition), other factors may 
cause increase in GL among PwGDM, including insulin resistance caused by 
pregnancy. Moreover, in mouse experiments, oxytocin was shown to be involved in 
gluconeogenesis.[28] It is becoming clear that oxytocin regulates glucose metabolism 
in the body,[29] perhaps through a mechanism that leads to some blood sugar 
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stabilization. Further studies are needed to clarify the factors affecting glucose 
kinetics during labor. 
From this study, it was found that PwGDM cases can be managed using the same 
management as for PwNGT cases, because the presence or absence of GDM did not 
affect GL. Furthermore, it was found that with the increase in GL, there was no 
influence on perinatal and neonatal prognosis, due to the time period. According 
toMaritza et al., these data suggest that apolicy for routine insulin infusion in women 
with GDM, or in women with GDM prescribed with insulin, is not necessary. 
Furthermore, the use of a dextrose/ insulin infusion during labor and prior to delivery 
was not associated with a lower risk of neonatal hypoglycemia. When maternal GL 
were examined, we also did not find that infusions modified the risk of neonatal 
hypoglycemia.[30] Thus, these CGM-based findings of glucose kinetics during labor 
may provide the basis for reviewing and revising the current management methods 
that may be required for expectant mothers. 
Our study was subject to some limitations. The number of patients was relatively 
small, and the investigation was performed at a single facility. Thus, selection bias 
may have occurred. Furthermore, a comparative study was not carried out between 
groups allowed to freely eat or drink or those under the current management system 
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involving fasting and intravenous infusion. In addition, in this study, all women with 
GDM did not receive insulin treatment between the active labor phase and 
postpartum. Women with GDM requiring insulin might be treated with a different 
protocol during delivery. 
Further multicentered prospective studies involving more patients would provide more 
definitive data to clarify the significance of our findings. 
Inconclusion, we clarified glucose kinetics during labor for both PwGDM and 
PwNGT. Interestingly, during labor, both the PwGDM and PwNGT groups showed 
similar changes in GL over time. GL peaked in period 3 directly after parturition in 
both the PwGDM and PwNGT groups. During delivery, PwGDM who regularly 
measured their own GL could be managed using the same nutritional management 
methods as those for PwNGT. 
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Figure 1. Study enrollment flow chart of pregnant women with gestational 
diabetes mellitus and normal glucose tolerance. 
PwGDM: Pregnant women with gestational diabetes mellitus during labor; PwNGT: 
pregnant women with normal glucose tolerance 
Figure 2. Continuous glucose monitoring levels during labor for one pregnant 
woman with gestational diabetes mellitus. 
PwGDM: Pregnant women with gestational diabetes mellitus, GL: Glucose Levels, 
SG: Sensor glucose, BG: blood glucose, GDM: gestational diabetes mellitus, SMBG: 
self-monitoring of blood glucose, 
Figure 3. Assessment of glucose kinetics via real-time continuous glucose monitoring 
during labor for 18 pregnant women with gestational diabetes mellitus and 22 pregnant 
women with normal glucose tolerance at four time points. Mean: 95% CI; main effect: 
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period F(2.12,80.51)=9.484; P=0.00014; main effect: DMF(1,38) = 2.069, P=0.159. CI, 
confidence interval; PwGDM, pregnant women with gestational diabetes mellitus; 
PwNGT, pregnant women with normal glucose tolerance; SG, sensor glucose. 
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